Navigation Links
Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics

Trophos Describes Identification, Characterization and Broad Neuroprotective Properties of TRO19622 in Journal of Pharmacology and Experimental Therapeutics

Neurodegenerative Disease Specialists Publish Details of a Novel Drug Candidate for ALS That Targets Mitochondrial Proteins

MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that a publication entitled "Identification and characterization of TRO19622 (cholest-4-en-3-one, oxime), a novel drug candidate for amyotrophic lateral sclerosis" has been accepted and published online May 11, 2007 in the Journal of Pharmacology And Experimental Therapeutics (J Pharmacol. Exp. Ther. 2007 May 11; [Epub ahead of print]).

Amylotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease in the USA, is a progressive and fatal neurological disease that is estimated to affect about 100,000 people worldwide. There is no cure for ALS. The only drug approved for ALS is riluzole (Rilutek(R), Sanofi-Aventis), which has been demonstrated to confer some survival benefit to ALS patients.

The studies reported in the paper by Bordet et al., (see below) identify two protein targets of TRO19622 present in the outer mitochondrial membrane suggesting that the compound has potential in a range of additional commercially attractive therapeutic indications involving mitochondrial dysfunction, including painful neuropathies. The publication describes the models of motor neuron disease employed to support the use of this compound to treat ALS, as well as spinal muscular atrophy. TRO19622 is currently in a Phase IIa clinical trial to establish its efficacy as a treatment for painful diabetic neuropathy.

TRO19622 is representative of novel compounds identified using the proprietary neuronal cell screening platform developed at Tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
8. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
9. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
10. JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:5/23/2013)... 24 de mayo de 2013  Volcano Corporation ... y fabricante de herramientas de precisión para terapia ... de la enfermedad vascular periférica y coronaria, anunció ... Ad enosine V asodilator I ndependent ... la sesión de ensayo clínico hot line late ...
(Date:5/23/2013)... 2013 Amgen (NASDAQ: AMGN ) will ... Conference on Thursday, May 30, 2013, at the Westin Boston ... a.m. Eastern Daylight Time. Arvind Sood , ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... , April 23, 2010 , , , ... A Migraine For Pharma Forecasters , , , ... up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast these areas. ... Dealing with uncertainties is no easy task. With a number ...
... TOKYO , April 23 Astellas Pharma Inc. (TSE: ... $52 per share for all of the currently outstanding shares ... Inc. (Nasdaq: OSIP ) to 5:00 p.m. New ... further extended.  The tender offer was previously set to expire at 12:00 ...
Cached Medicine Technology:MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3Expiration Date of OSI Offer Extended to May 17, 2010 2Expiration Date of OSI Offer Extended to May 17, 2010 3Expiration Date of OSI Offer Extended to May 17, 2010 4
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 Country music fans ... Aldean's opening act in 2012. Due to overwhelming demand, Luke ... during 2013. , Luke Bryan has written successful songs ... nearly a decade ago back in the mid-2000 era. Some ... and Travis Tritt. , When Luke was 14, his parents ...
(Date:5/25/2013)... May 25, 2013 Imagine running the air ... energy loss, hot air and wasted energy! If the home ... a fireplace or clothes dryer, that may be just what ... these often overlooked holes waste energy in the form of ... and cooling loss in the home. , Drafts occur through ...
(Date:5/25/2013)... May 25, 2013 An experienced Chandler ... in partnership with JD Media Surge, LLC. , ... now available and, depending on the treatment, can be ... routine visit, the best method will be chosen for ... during a visit. A special peroxide-based whitening gel is ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Actos ... underway in U.S. District Court, Western District of Louisiana, ... According to a Case Management Order issued on May ... filing of contested motions in the Actos bladder cancer ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
Breaking Medicine News(10 mins):Health News:Luke Bryan Tickets: Prices Slashed on Luke Bryan Tickets in Raleigh, Bethel, Camden, Peoria, Nashville, Hartford, Chicago, Boston, Atlanta, Indianapolis & SaratogaSprings 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3
... Pavilion Offers Unique Skills Training Where Patients, Replicate Real-World ... ... Personal Support, LOMA LINDA, Calif., ... Empire,s leader in physical,rehabilitation for survivors of stroke, fractures, amputations, ...
... 2008) MIT graduate student and synthetic biologist ... pose threats to human health. His current mission: ... M.D. candidate and Ph.D. in the Harvard-MIT Division ... $30,000 Lemelson-MIT Student Prize for inventing processes that ...
... association of ABG with thyroid disorders (TD) was first ... the association between Pernicious Anemia (PA) and Thyroiditis on ... recently systematic studies have focused on this frequently overlooked ... January 28, 2008 in the World Journal of Gastroenterology ...
... to Host Conference Call on Tuesday, March 4th at 2:00 ... Hooper Holmes,Inc. (Amex: HH ) today announced that it ... Tuesday, March 4th at 2:00 pm ET. The,Company,s newly- appointed ... the call., The focus of the conference call will ...
... the findings , , TUESDAY, Feb. 26 (HealthDay News) -- ... for people with varying degrees of depression, the drugs ... depression, a new study suggests. , "Although patients get ... when they take a placebo, and the difference in ...
... YORK, Feb. 27 American Oriental,Bioengineering, Inc. (NYSE: ... and nutraceutical products, today announced that,it plans to release ... morning of Thursday, March 6, 2008 before the market ... that morning at 8:00 am ET to,discuss results. Listeners ...
Cached Medicine News:Health News:Loma Linda University Medical Center Celebrates Groundbreaking on Inland Empire's Most Comprehensive Rehabilitation Center 2Health News:Loma Linda University Medical Center Celebrates Groundbreaking on Inland Empire's Most Comprehensive Rehabilitation Center 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 2Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 4Health News:Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease? 2Health News:Hooper Holmes to Provide Business Update 2Health News:Only Severely Depressed Benefit From Antidepressants: Study 2Health News:American Oriental Bioengineering to Report Fourth Quarter and Full Year 2007 Financial Results 2
Primary and Posterior Stabilized Components....
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
... The Natural Knee design ... a proprietary CSTi porous coating ... active patients, a unique bone ... deepened trochlear groove to maximize ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Medicine Products: